Cariprazine in the treatment of schizophrenia: A proof-of-concept trial

International Clinical Psychopharmacology

Volumn 31, Issue 2, 2016, Pages 61-68

  Durgam, Suresh ^a   Litman, Robert E ^b   Papadakis, Kelly ^a   Li, Dayong ^a   Németh, György ^c   Laszlovszky, István ^c  

^a FOREST RESEARCH INSTITUTE   (United States)

^b CBH Health   (United States)

^c GEDEON RICHTER LTD   (Hungary)

Author keywords

Antipsychotic; Cariprazine; Dopamine D3; Schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; CARIPRAZINE; LORAZEPAM; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AGED; AGITATION; AKATHISIA; ARTICLE; BACKACHE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NOSE OBSTRUCTION; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TOOTH PAIN; TREMOR; VOMITING; CLINICAL TRIAL; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84957846109     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000110     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-text revision, 4th Edition. Washington, DC: American Psychiatric Association; 2000.
2. Ban TA (2007). Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat 3:495-500.
3. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
4. Crossley NA, Constante M, McGuire P, Power P (2010). Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196:434-439.
5. Duman RS, Duric V, Banasr M, Adham N, Kiss B, Gyertyán I (2012). Cariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic unpredictable stress model of anhedonia. Neuropsychopharmacology 38:S84.
6. Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I (2014). An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res 152:450-457.
7. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. (2015). Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase III, randomized, double-blind, placebo-and active-controlled trial. J Clin Psychiatry (in press).
8. Gurevich EV, Joyce JN (1999). Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60-80.
9. GuyW(1976a). The Abnormal Movement Scale ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. pp. 218-222.
10. Guy W (1976b). The Clinician Global Severity and Impression scales ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. pp. 218-222.
11. Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, et al. (2011). Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 59:925-935.
12. Joyce JN, Millan MJ (2005). Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917-925.
13. Kane JM, Correll CU (2010). Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71:1115-1124.
14. Kane JM, Zukin S,Wang Y, Lu K, Ruth A, Nagy K, et al. (2015). Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol 35:367-373.
15. Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090.
16. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
17. Kay SR, Opler LA, Spitzer RL, Williams JB, Fiszbein A, Gorelick A (1991). SCIDPANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry 32:355-361.
18. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633-647.
19. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2012). Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry 73:856-864.
20. Kirkpatrick B, Fenton WS, Carpenter WT Jr., Marder SR (2006). The NIMHMATRICS consensus statement on negative symptoms. Schizophr Bull 32:214-219.
21. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333:328-340.
22. Kiss B, Horti F, Bobok A (2012). Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res 136 (Suppl 1):S190.
23. Laszy J, Laszlovszky I, Gyertyán I (2005). Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 179:567-575.
24. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR (2005). What does the PANSS mean? Schizophr Res 79:231-238.
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
26. Nasrallah H, Tandon R, Keshavan M (2011). Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. Epidemiol Psychiatr Sci 20:317-327.
27. Nord M, Farde L (2011). Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97-103.
28. Papp M, Gruca P, Lasoń-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I (2014). Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol 25:567-574.
29. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
30. Slifstein M, Abi-Dargham A, D'Souza DC, RE C, Laszlovszky I, Durgam S, et al. (2013). Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical pet study with [11C]-(+ )-PHNO. Neuropsychopharmacology 38:S520.
31. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (2006). The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25-43.
32. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611-622.
33. Tandon R, Nasrallah HA, Keshavan MS (2010). Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res 122:1-23.
34. Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C (2013). Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 226:91-100.